

Laboratory Research
to Discover
New Approaches to Treat Cancer

Carol L. Williams, Ph.D.

Co-Director, Cancer Biology Program
Professor, Department of Pharmacology

Medical College of Wisconsin



Our research is aimed at developing
better treatments for cancer

Focus on Metastasis

(spread of cancer cells through the body)


Metastasis is the major cause of death from cancer


- Primary tumors can be surgically removed
- Metastasis causes multiple tumors to form throughout the body


To develop better treatments,
we need to understand how metastasis occurs


The primary tumor
consists of proliferating
(multiplying)
cancer cells


During metastasis,
the cancer cells
migrate away from the
primary tumor,
and enter
the blood stream



















Which of these 23,000 different proteins are needed for cancer cells to proliferate and migrate?



Problem:
Normal cells and cancer cells often use the same proteins to help the cells proliferate and migrate

Which of these 23,000 different proteins are needed for cancer cells to proliferate and migrate?



Problem:
Normal cells and cancer cells often use the same proteins to help the cells proliferate and migrate

Solution:
Cancer cells often make very high amounts of these proteins, so the cancer cells proliferate more and migrate faster than normal cells

Goal:

Identify proteins that are made in abnormally high amounts by cancer cells, because cancer cells might use these proteins for their increased proliferation and migration

Identify ways to block the function or production of these proteins in cancer cells to diminish tumor formation and metastasis

Pipeline to Develop New Ways to Treat Cancer


Identify Therapeutic Targets	<ul style="list-style-type: none">• Identify proteins made in higher levels in cancer cells compared to normal cells• These proteins are called "therapeutic targets"
------------------------------	--


Pipeline to Develop New Ways to Treat Cancer


Identify Therapeutic Targets	<ul style="list-style-type: none">• Identify proteins made in higher levels in cancer cells compared to normal cells• These proteins are called "therapeutic targets"
↓	
Validate the Targets	<ul style="list-style-type: none">• Confirm that the identified proteins actually cause cancer, instead of being just a consequence of the cancer

Pipeline to Develop New Ways to Treat Cancer

Identify Therapeutic Targets	<ul style="list-style-type: none">• Identify proteins made in higher levels in cancer cells compared to normal cells• These proteins are called "therapeutic targets"
↓	
Validate the Targets	<ul style="list-style-type: none">• Confirm that the identified proteins actually cause cancer, instead of being just a consequence of the cancer
↓	
Develop ways to Modulate the Target	<ul style="list-style-type: none">• Develop drugs to lower the level (or inhibit the function) of the protein in the cancer cells







Goal: Stop joggers from running faster than pedestrians

- Identify special items that increase the speed of joggers
- Develop ways to take these special items away from joggers, so the joggers move slower

Identify Therapeutic Targets

- Special running shoes are worn by joggers



↓

Validate the Targets

- Joggers run slower when we take away their special running shoes
- Special running shoes are needed to help joggers run faster



↓

Develop ways to Modulate the Target

- Developing ways to stop joggers from wearing special running shoes is worthwhile, because it will slow joggers' speed

- By comparing joggers and pedestrians, we can identify which items make joggers run faster
- Special shoes help joggers run faster
- Taking away these special shoes make joggers run slower




- By comparing cancer cells and normal cells, we can identify which proteins (among the 23,000 made by cells) cause the cancer cells to grow more quickly
- Can we take away these special proteins from cancer cells, so they grow more slowly?

Breast Tumor



Normal Breast





We compare patients' breast tumors with normal breast tissue, to identify proteins that are made more by the tumor cells

We discovered that the protein called **SmgGDS** (pronounced "smidge G D S") is made more in the tumor cells than in the normal cells

Blue Color:
Low SmgGDS level


Brown color:
High SmgGDS level

Normal Breast Tissue

Ductal Carcinoma in situ (DCIS)

A later stage breast tumor also has dark brown color, indicating that the breast cancer cells are making high amounts of SmgGDS protein




Infiltrating Ductal Carcinoma (IDC)

Benign normal breast tissue

A

SmgGDS is made in very high levels in metastatic cancer cells




Metastatic Breast Cancer

A

Brown Color: High SmgGDS level

Blue Color: Low SmgGDS level



Normal Breast Tissue

B

Developing New Ways to Treat Cancer by Targeting the Protein Called SmgGDS

Identify Therapeutic Targets

- SmgGDS is made more in cancer cells compared to normal cells.
- SmgGDS is a therapeutic target

↓


Validate the Targets


- Cancer cells proliferate less, and move slower, when we stop them from making SmgGDS
- SmgGDS is a validated target in breast, lung, prostate, and pancreatic cancer
(Google: SmgGDS Williams Cancer [breast, lung, etc.])


↓


Develop ways to Modulate the Target


- Can we develop drugs to lower the level of SmgGDS in cancer cells?














But not all of these expectations were met ...

Erlotinib slows lung cancer progression, but only in 10 - 20% of patients with lung cancer

- Extensive laboratory research indicated that erlotinib only blocks EGF Receptors that have a special mutation
- Epidemiological and genotyping studies indicated that only 10 - 20% of patients have lung tumors with the mutant form of the EGF Receptor

The different forms of EGF Receptor are like running shoes that have different colors



All joggers have running shoes, but these shoes come in different colors


- Only blue running shoes are removed by erlotinib

Treat with Erlotinib:



Most lung tumors have EGF Receptors, but these receptors come in different forms

- Only mutant EGF Receptors are inhibited by erlotinib



Personalized Medicine:

Each patient's tumor can be tested to identify the form of EGF Receptor made by their cancer cells

This information can be used to tailor the treatment for each patient

The diagram illustrates three scenarios for EGF Receptor in cancer cells:

- Mutant EGF Receptor:** A cancer cell with a mutant receptor. An arrow points down to the text: "The patient might be helped by treatment with erlotinib".
- Wildtype EGF Receptor:** A cancer cell with a wildtype receptor. An arrow points down to the text: "The patient will *not* be helped by treatment with erlotinib".
- Cancer cells do not make the EGF Receptor:** A cancer cell without an EGF Receptor. An arrow points down to the text: "The patient will *not* be helped by treatment with erlotinib".

Summary

- Basic laboratory research is required to develop better ways to prevent, diagnose, and treat cancer
- Cancer cell proliferation and migration are often studied, because these characteristics contribute to cancer metastasis
- Scientists compare the features of normal cells and cancer cells to identify which features are abnormal in cancer cells

Summary

- Good therapeutic targets are proteins that
 - are made in abnormally high amounts by cancer cells
 - promote the proliferation and migration of cancer cells
- Scientists develop drugs that stop the abnormal protein (therapeutic target) from functioning or being made in cancer cells
- Clinical trials are conducted to test the ability of newly developed drugs to slow tumor growth and inhibit metastasis
